Prelude Capital Management’s CVS Health CVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $827K | Buy |
11,518
+8,895
| +339% | +$685K | 0.06% | 349 |
|
|
2025
Q4 | $208K | Sell |
2,623
-14,666
| -85% | -$1.16M | 0.02% | 1040 |
|
|
2025
Q3 | $1.3M | Buy |
17,289
+13,609
| +370% | +$933K | 0.1% | 250 |
|
|
2025
Q2 | $254K | Sell |
3,680
-2,235
| -38% | -$147K | 0.02% | 690 |
|
|
2025
Q1 | $401K | Buy |
+5,915
| New | +$354K | 0.03% | 582 |
|
|
2023
Q4 | – | Sell |
-3,844
| Closed | -$268K | – | 1165 |
|
|
2023
Q3 | $268K | Buy |
3,844
+748
| +24% | +$53K | 0.02% | 736 |
|
|
2023
Q2 | $214K | Sell |
3,096
-2,818
| -48% | -$201K | 0.01% | 817 |
|
|
2023
Q1 | $439K | Sell |
5,914
-21,593
| -79% | -$1.81M | 0.03% | 505 |
|
|
2022
Q4 | $2.56M | Buy |
27,507
+2,294
| +9% | +$221K | 0.13% | 174 |
|
|
2022
Q3 | $2.4M | Buy |
25,213
+1,385
| +6% | +$137K | 0.09% | 188 |
|
|
2022
Q2 | $2.21M | Sell |
23,828
-16,670
| -41% | -$1.63M | 0.06% | 264 |
|
|
2022
Q1 | $4.1M | Buy |
+40,498
| New | +$4.25M | 0.12% | 157 |
|
|
2021
Q3 | – | Sell |
-11,338
| Closed | -$950K | – | 1796 |
|
|
2021
Q2 | $946K | Sell |
11,338
-15,599
| -58% | -$1.28M | 0.03% | 641 |
|
|
2021
Q1 | $2.03M | Buy |
26,937
+22,784
| +549% | +$1.66M | 0.05% | 330 |
|
|
2020
Q4 | $284K | Sell |
4,153
-6,346
| -60% | -$413K | 0.01% | 935 |
|
|
2020
Q3 | $613K | Buy |
+10,499
| New | +$653K | 0.03% | 390 |
|
|
2020
Q2 | – | Sell |
-13,426
| Closed | -$845K | – | 2002 |
|
|
2020
Q1 | $797K | Buy |
13,426
+10,641
| +382% | +$710K | 0.05% | 245 |
|
|
2019
Q4 | $207K | Buy |
+2,785
| New | +$196K | 0.01% | 849 |
|
|
2019
Q3 | – | Sell |
-17,457
| Closed | -$1.03M | – | 1767 |
|
|
2019
Q2 | $951K | Buy |
17,457
+5,557
| +47% | +$299K | 0.05% | 354 |
|
|
2019
Q1 | $642K | Buy |
11,900
+6,327
| +114% | +$391K | 0.04% | 437 |
|
|
2018
Q4 | $365K | Buy |
+5,573
| New | +$416K | 0.02% | 557 |
|
|
2016
Q4 | – | Sell |
-11,501
| Closed | -$1.02M | – | 1590 |
|
|
2016
Q3 | $1.02M | Buy |
11,501
+3,738
| +48% | +$353K | 0.11% | 209 |
|
|
2016
Q2 | $743K | Buy |
7,763
+6,633
| +587% | +$661K | 0.1% | 222 |
|
|
2016
Q1 | $117K | Buy |
1,130
+741
| +190% | +$72.1K | 0.02% | 712 |
|
|
2015
Q4 | $38K | Sell |
389
-15,710
| -98% | -$1.54M | 0.01% | 1097 |
|
|
2015
Q3 | $1.55M | Sell |
16,099
-789
| -5% | -$82.9K | 0.23% | 112 |
|
|
2015
Q2 | $1.77M | Buy |
16,888
+4,369
| +35% | +$446K | 0.25% | 97 |
|
|
2015
Q1 | $1.29M | Buy |
12,519
+9,101
| +266% | +$921K | 0.18% | 145 |
|
|
2014
Q4 | $329K | Buy |
3,418
+2,418
| +242% | +$213K | 0.05% | 464 |
|
|
2014
Q3 | $80K | Sell |
1,000
-200
| -17% | -$15.8K | 0.01% | 1188 |
|
|
2014
Q2 | $90K | Sell |
1,200
-898
| -43% | -$67.9K | 0.01% | 1130 |
|
|
2014
Q1 | $157K | Buy |
2,098
+498
| +31% | +$35.2K | 0.02% | 819 |
|
|
2013
Q4 | $115K | Sell |
1,600
-2,320
| -59% | -$149K | 0.02% | 818 |
|
|
2013
Q3 | $222K | Sell |
3,920
-355
| -8% | -$21.2K | 0.04% | 507 |
|
|
2013
Q2 | $244K | Buy |
+4,275
| New | +$248K | 0.05% | 402 |
|
Other funds holding CVS
VCM
VPM
Prelude Capital Management's CVS Position: Q1 2026 in Review
Prelude Capital Management increased its CVS Health (CVS) stake by 339% in Q1 2026, buying an estimated $685K and bringing the position to 11,518 shares worth $827K. The position accounts for 0.06% of the portfolio, ranked #349.
Prelude Capital Management first reported a position in CVS in Q2 2013 and has held it in 35 quarters since. The position peaked at $4.1M in Q1 2022. 1,865 funds tracked by Wall St. Rank hold CVS as of Q1 2026.
- Prelude Capital Management held 11,518 shares of CVS Health worth $827K as of Q1 2026.
- Prelude Capital Management bought 8,895 CVS Health shares in Q1 2026, an estimated $685K.
- CVS Health made up 0.06% of Prelude Capital Management's portfolio in Q1 2026, its #349 holding.
- Prelude Capital Management first reported a position in CVS Health in Q2 2013 and has held it in 35 quarters since.
- Prelude Capital Management's CVS Health position peaked at $4.1M in Q1 2022.
- 1,865 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.